Research programme: leptin gene transcription activators - Japan Tobacco/Amgen

Drug Profile

Research programme: leptin gene transcription activators - Japan Tobacco/Amgen

Alternative Names: Leptin gene transcription activators research programme - Japan Tobacco/Amgen

Latest Information Update: 20 Nov 2003

Price : $50

At a glance

  • Originator Japan Tobacco; Tularik
  • Developer Tularik
  • Class
  • Mechanism of Action Genetic transcription stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetes mellitus; Obesity

Most Recent Events

  • 20 Nov 2003 Discontinued - Preclinical for Diabetes mellitus in USA (PO)
  • 20 Nov 2003 Discontinued - Preclinical for Obesity in USA (PO)
  • 20 Aug 2002 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top